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About 1% of women suffer from premature ovarian failure, which leads to a significant deterioration in the life quality. Most often 
this condition is caused by performed chemotherapy, autoimmune diseases, surgery performed on ovaries, uterus, or fallopian 
tubes. The aim of this study was to compare different approaches of tissue and cell therapy in restoring the sexual function in case 
of ovarian failure induced by chemotherapy. Materials and Methods: The study was carried out in BALB/c mice with the modeled 
ovarian failure, induced by cyclophosphamide and busulfan. The restoration dynamics of ovarian and sexual function, liver and 
kidneys after application of cryopreserved explants, cryoextract, placental mesenchymal stem cells, those of adipose tissue has been 
studied. Results: It has been shown that the use of various methods of cell and tissue therapy has comparable efficacy when treating 
an ovarian failure induced by chemotherapy. The most rapid and complete restoration of the reproductive system, liver and kidneys 
was observed when using the placental explants, extract and cells, but not with the use of mesenchymal stem cells of adipose tissue. 
No recovery of fertility in this experiment was observed. Conclusion: Various methods of cellular and tissue therapy are perspective 
in treatment of the chemotherapy complications. More effective are placental derivates.
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In developed countries, the physiological age of the 
menopause onset is 50–52 years. Premature ova­
rian failure (POF) is observed in 1% of women under 
40 and 0.1% under 30 years, among those 37% is due 
to iatrogenic causes (mainly after onco logy treat­
ment), 25% — to idiopathic, 19% — to genetic, 19% — 
to autoimmune [1, 2]. Complications of premature 
menopause are not only the lack of fertility, decreased 
libido and amenorrhea, but also a sharp deterioration 
in the quality of life, psycho­emotional disorders, os­
teoporosis, increased mortality from cardiovascular 
diseases and strokes [3, 4]. Traditional hormone 
therapy requires constant drug intake, has a number 
of limitations, does not restore fertility and does not 
correct pathological changes in target organs [5]. 
Cell therapy, protection of the ovarian reserve by the 
administration of gonadotropin­releasing agonists 
prior to the chemotherapy, cryopreservation of ovarian 
tissue, gametes, embryos are referred to perspective 
methods of POF correction [6, 7].
The most curative and numerous groups of the 
patients with POF are the women with iatrogenic and 
autoimmune origin of the disease [1, 3, 8]. It should 
be noted that the use of methods of cell and tissue 
therapy, unambiguously shown in autoimmune dis­
eases, is controversial in the patients with oncologic 
pathology. Along with the classical postulate, the wor­
sening of cancer prognosis with the use of stimulants 
and during pregnancy, there are the data on the ability 
of stem cells to suppress tumor growth independently 
and as a “vector” [11–14] as well as about the dif­
ferentiated approaches to the restoration of fertility 
in the women who underwent oncology [15, 16]. Most 
researchers use the introduction of various stem cells, 
often of either placental or adipose origin directly into 
the ovary, to restore the function of the ovaries that 
is effective in improving sexual function and ferti­
lity [17–20], but requires surgery, affects less other 
organs, demands the use of non­standardized culture 
techniques.
The research aim was to compare the different 
approaches of tissue and cell therapy when restoring 
chemotherapy­induced ovarian failure.
MATERIALS AND METHODS
In the research we used 90 female 6­months old 
BALB/c mice weighing 20.2 ± 0.4 g with a regular 
estrous cycle, which were divided into 6 groups 
of 15 animals each: 1 — the animals with modeled POF 
with no treatment, 2 — the animals with modeled POF 
and treatment with cryopreserved placental explants, 
3 — the animals with modeled POF and treatment with 
placental cryoextract, 4 — the animals with modeled 
POF and treatment with cryopreserved placental 
mesenchymal stem cells (MSCs), 5 — the animals 
with modeled POF and treatment with cryopreserved 
adipose tissue MSCs, 6 — intact animals.
POF was simulated according to the standard 
method [20] by means of administration of cyclophos­
phamide at a dose of 200 mg/kg (Baxter Oncology, 
Germany) and busulfan (Aspen Pharma, Germany) 
at a dose of 20 mg/kg. Cyclophosphamide (200 mg) 
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was dissolved in 20 ml of phosphate buffered saline 
(PBS), busulfan (20 mg) dissolved in 2 ml of dime­
thylsulfoxide was added, and intraperitoneally admini­
stered by 0.5 ml to each animal.
Placental explants were obtained from the human 
placenta by fragmentation of the villi as reported 
previously [21]. The placental extract was obtained 
by means of previously described method [22]. With 
this aim the human placenta delivered within 3 hr af­
ter the cesarean section was fragmented, two parts 
of PBS were added to one part of the placental tissue, 
three times cooled by immersion in liquid nitrogen 
and warmed in a water bath at 37 °C, centrifuged 
at 1500 rpm/min, the supernatant was removed and 
used. The placental MSCs were obtained by the 
method previously described, wherein the placenta 
cells were obtained by enzymatic method using 0.25% 
trypsin [23]. The cells were phenotyped earlier, CD90, 
CD73, CD105 markers were present on their surface, 
CD34 was absent, they had the ability to differentiate 
into osteogenic, adipogenic and chondrogenic di­
rections [23]. MSCs of adipose tissue were obtained 
by the method [18] using enzymatic treatment with 
collagenase.
For a number of reasons, the cell therapy necessi­
tates the use of cryopreserved objects [22]. Placental 
explants and MSCs were cryopreserved according 
to the previously used protocol [23], the DMEM with 
a high glucose content and L­glulamine (BioWest, 
France) enriched with 10% fetal bovine serum (Lonza, 
Germany) and 10% dimethylsulfoxide (Sigma, USA) 
was used as the cryoprotective medium, were frozen 
in Nunc cryotubes (USA) using isopropanol contain­
ers. Mr. Frosty™ Freezing Container (Thermo Fisher 
Scientific, USA) at a rate of 1 °C down to −70 °C, fol­
lowed by an immersion into liquid nitrogen. Thawing 
was performed in a water bath at 37 °C.
Treatment started 2 weeks later the chemotherapy. 
Cryopreserved explants of the placenta were intra­
muscularly injected by 10 mg through a thick needle. 
The placenta extract was intramuscularly injected 
by 0.01 ml once a day for 5 days. MSCs were intraperi­
toneally introduced once at 1•105/animal. The dose 
and mode of administration were used in accordance 
with the recommendations for drug testing and pub­
lications [18, 20, 24].
The dynamics of changes in the weight of animals 
was studied. The function of the ovaries was examined 
by the method of vaginal cytology. The sexual func­
tion was examined by counting the number of vaginal 
plugs. Four weeks after the chemotherapy, 5 animals 
from each group were removed from the experiment, 
the preparations of ovaries, the uteri as organs of re­
productive system, liver and kidneys as detoxification 
organs were histologically examined. After 12 weeks, 
all the animals were removed from the experiments.
During the experiment, the animals were exposed 
to natural light, they received standard food ad libitum. 
To assess sexual and reproductive functions, females 
were kept with 6­months old intact BALB/c males 
at 1:3 ratio. The maintenance of animals corresponded 
to the current rules on equipping and keeping the 
vivarium.
The results were statistically processed by the 
ANOVA method using Past V. 3.15 (Hammer, Natural 
History Museum, University of Oslo) software.
The placentas were obtained with the informed 
consent of women after the cesarean section surgery. 
The experiments were carried out in accordance with 
the “General Principles of the Experiments in Animals”, 
approved by the 5th Congress in Bioethics (Kyiv, 2013) 
and coordinated with the statements of the “European 
Convention for the Protection of Vertebrate Animals 
Used for Experimental and Other Scientific Purposes” 
(Strasbourg, 1986), agreed with the Committee in Bio­
ethics of the Institute for Problems of Cryobiology and 
Cryomedicine of the National Academy of Sciences 
of Ukraine (Protocol No. 2 of June 3rd, 2013).
RESULTS AND DISCUSSION
During studying the dynamics of animals’ weight 
for 8 weeks, the body mass of mice of the control 
group increased from 19.8 up to 22.2 g, being the 
feature of mice of this age. In all the groups after 
chemotherapy, the weight dropped sharply down 
to 17.5 g followed by a slow recovery. Simultaneously, 
at the same time, we found a change in their general 
condition, i.e. hypodynamia, felted hair, eye opacity. 
In the group with no treatment, the mice were restored 
to the intact group for 8 weeks. The group injected with 
the placenta explants restored the weight for 5 weeks 
after chemotherapy, the group that received the pla­
cental cryoextract did for 6 weeks, and the groups did 
after the introduction of the cells for 7 weeks (Fig. 1, a). 
Simultaneously with the restoration of weight, the 
general condition and appearance of the animals 
improved.
When investigating the number of estrous cycles 
by the method of vaginal cytology in the control group, 
a regular cycle was observed in all the animals. In the 
animals after chemotherapy, the absence of superficial 
epithelium was noted, it began to appear 5 weeks after 
chemotherapy, and after 8 weeks it was observed in 50% 
of mice that was in accordance with the reports on this 
model [20]. In the group after the introduction of pla­
cental explants, the cyclicity was restored quickly, and 
6 weeks after chemotherapy it was observed in 100% 
of the animals. The use of placental cryoextract restored 
the estrous cycle in 80% of the animals to the 5th week. 
The use of cells made it possible to achieve a result to the 
week 7–8 in 70% of animals (Fig. 1, b). It should be noted 
that after chemotherapy in most animals, a regular 4­day 
estrous cycle was not restored, there was a periodic ap­
pearance of a superficial epithelium in the smear of kera­
tinized cells for a period from 3 to 8 days, which indicated 
the estrogen saturation of the organism, possible without 
ovulation. Restoration of the estrous cycle was correlated 
with the weight of mice, so when comparing the weights 
of the animals and the onset of regular estrous cycle, 
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it was noted that mice weighing less than 18 g rarely had 
a regular estrous cycle.
When studying the sexual function it has been 
shown that the number of effective couplings in the 
group after chemotherapy made 30% at week 8 that 
corresponded to the published data for the model 
(Fig. 1, c). With the use of various methods of therapy, 
this index increased up to 60–80%, higher when the 
explants were used, less if using the placental cryo­
extract and cells were applied.
In the investigation of reproductive function 90% 
of the control group females became pregnant during 
the experiment, an average number of fetuses was 12. 
None of the females after the chemotherapy became 
pregnant. According to the literature data for this model, 
restoration of fertility was described in the case when 
the cells were introduced directly into the ovary [20].
When the animals were removed from the experi­
ment at week 4 in intact animals the ovaries were of the 
usual size with follicles of various maturity (Fig. 2, a), 
all the layers and glands were visible in the uterus 
(Fig. 2, b), the kidneys were of usual structure with pre­
served glomerular and tubular apparatus (Fig. 2, c), 
the liver with preserved lobular structure (Fig. 2, d). 
In the animals after chemotherapy, the decreased size 
of uteri and ovaries has attracted the attention. In his­
tological examination a reduced number of primary 
follicles, complete absence of secondary ones, sharp 
atrophy, and shrinkage cells and organ as a whole were 
found in ovaries (Fig. 2, e). In uterus a strong atrophy 
with thinning of all the layers was observed (Fig. 2, f). 
Changes in the reproductive system did not differ in all 
the groups receiving chemotherapy. In the kidneys 
a sharp edema of the cortical and medular layers was 
observed (Fig. 2, g), however, in the groups using the 
placental explants and cryoextract only a part of the 
kidney was edematous, not more than a half of the 
sections’ area (Fig. 2, h). In the study of liver, edema 
and its impaired lobular structure were observed in all 
the groups (Fig. 2, i), however, in the groups treated 
with cryoextract and placenta explants, the lobular 
structure was partially preserved (Fig. 2, j).
After 12 weeks when animals were removed from 
the experiment in the group after chemotherapy 
without treatment, a sharp increase in adipose tissue 
in the abdominal cavity was observed. The ovaries 
were reduced in size, histological examination indi­
cated the absence of structural elements in them: yel­
low bodies, primordial, primary, secondary follicles, 
the stroma was filled with large cells (Fig. 3, a). The 
restoration of estrogen saturation of the body in this 
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Fig.1. Dynamics of changes in body mass of animals (а), re­
covery of estrous cycles (b) and sexual activity (с), mean ± SD. 
*p < 0.05 (compared with control)
Fig. 2. Morphological changes in organs of studied animals in 4 weeks after chemotherapy: a–d — control group, e–j — experimental 
groups. Hematoxylin­eosin, scale bar 100 mm
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group of animals was evidently due to an adipose 
tissue, but not ovaries. Histological examination 
of uteri showed less pronounced atrophic events 
than at week 4 after chemotherapy, but the thinning 
of layers as well as endometrium and myometrium 
atrophy was significant, the lumen was enlarged, the 
number of glands decreased (Fig. 3, b). Histological 
examination of kidneys demonstrated the shrinkage 
of the glomeruli and a persistent edema of tubules 
(Fig. 3, c). In liver the foci of cirrhosis, disordered 
lobular structure, and areas of nuclear polymorphism 
were observed (Fig. 3, d).
In the study of the ovaries of animals treated with 
placental explants the structural elements were also 
absent, but the follicle­like formations, i.e. the rounded 
areas containing large cells with a light cytoplasm 
(Fig. 3, e) were also enlarged if compared with the pre­
vious group. Histological examination of uteri showed 
an increase in the number of glands, endometrial 
hyperplasia, myometrium thickening (Fig. 3, f), organ 
structure differed slightly from intact animals. In kid­
neys the minimal changes in glomerular and tubular 
apparatus were observed (Fig. 3, g). In liver the lobular 
structure was preserved, there were no cirrhosis foci, 
however polymorphism of nuclei was found (Fig. 3, h).
In animals treated with placental cryoextract in the 
ovaries, there were no typical elements, individual 
follicle­like structures were observed (Fig. 3, i) with the 
size of the ovaries smaller than in the previous group. 
Uterus was close to the intact (Fig. 3, j), liver was with 
preserved lobular structure, in some cases we found 
the cell polymorphism, heterogeneity. The kidneys 
had the preserved structure, there was a shrinkage 
of individual glomeruli.
When investigating the groups treated with MSCs 
of both a placental (Fig. 3, k, l) and adipose origins 
(Fig. 3, m, n), the structure of organs differed slightly. 
In both groups there were no typical elements in ova­
ries, the hyperplasia of either individual cells or cell 
groups was noted. The structure of uteri was close 
to native, with some atrophy of the layers, the num­
ber and size of glands were increased. In kidneys 
the structure was preserved, there was a shrinkage 
of some glomeruli. In liver we noted the preserved 
lobular structure, individual sites of accumulation 
of small nuclei.
In addition, it should be noted that a response 
of animals to chemotherapy and treatment was differ­
ent. So in the first group in the ovaries of one animal 
the folliculogenesis was preserved, but not there 
was no formation of yellow bodies and 12 weeks later 
no changes in the liver and kidneys. In one animal of the 
second group in response to the introduced explants 
a sharp endometrial hyperplasia was observed, with 
Fig. 3. Morphological changes in organs of studied animals in 12 weeks after chemotherapy: a–d — group 1; e–h, o — group 2; 
i–j, p — group 3; k, l — group 4; m, n — group 5. Hematoxylin­eosin, scale bar 100 mm
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complete ovarian atrophy (Fig. 3, o). One animal of the 
third group demonstrated a severe atrophy of the uterus 
at week 12 (Fig. 3, p), cirrhotic changes in the liver, de­
spite gaining the weight. However, the changes in the 
remaining animals in the groups were of the same type.
The performed studies enabled to draw the follow­
ing conclusions: the use of various methods of cell and 
tissue therapy (placental explants, cryoextract, cells) 
had a comparable efficacy when treating the ova rian 
failure, induced by chemotherapy. With systemic 
administration of drugs (non­topical), it is possible 
to restore kidneys, liver, ovarian function, but not fertil­
ity. The most rapid and complete restoration of repro­
ductive system, liver and kidneys was observed when 
using the organotypic culture and cryoextract of pla­
centa. The use of MSCs derived from various sources 
led to a slower recovery. Sensitivity to chemotherapy 
and treatment in individuals depended on the specific 
characteristics of an organism.
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